AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

AstraZeneca Finalizes Acquisition of Fusion Pharmaceuticals

NextEdge Admin

05 Jun 2024

2 min 3 sec

metastatic castration-resistant prostate cancer,Oncology

AstraZeneca has announced the successful completion of its acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing next-generation radioconjugates (RCs) for cancer treatment. This acquisition represents a significant advancement in AstraZeneca's mission to revolutionize cancer treatment by replacing conventional therapies like chemotherapy and radiotherapy with more targeted approaches.

By integrating Fusion's pipeline of RCs into its leading oncology portfolio, AstraZeneca gains access to innovative treatments, including FPI-2265, a potential new therapy for metastatic castration-resistant prostate cancer (mCRPC). FPI-2265 utilizes actinium-225, a promising radioisotope known for its ability to deliver potent radiation directly to cancer cells while minimizing damage to healthy tissue. This targeted approach holds the promise of improving treatment efficacy and reducing toxicity.

AstraZeneca's commitment to oncology innovation extends beyond this acquisition. The company is dedicated to understanding the complexities of cancer through scientific research and development, with the ultimate goal of providing life-changing medicines to patients across a spectrum of challenging cancers. Through persistent innovation, AstraZeneca has cultivated a diverse portfolio and pipeline, positioning itself at the forefront of transformative cancer care.

With a vision to redefine cancer treatment and ultimately eliminate cancer-related deaths, AstraZeneca is driving forward with determination and a focus on rewriting the future of cancer care.